Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 274

1.

Combinatorial screening using orthotopic patient derived xenograft-expanded early phase cultures of osteosarcoma identify novel therapeutic drug combinations.

Loh AHP, Stewart E, Bradley CL, Chen X, Daryani V, Stewart CF, Calabrese C, Funk A, Miller G, Karlstrom A, Krafcik F, Goshorn DR, Vogel P, Bahrami A, Shelat A, Dyer MA.

Cancer Lett. 2018 Nov 3;442:262-270. doi: 10.1016/j.canlet.2018.10.033. [Epub ahead of print]

PMID:
30395907
2.

Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial.

Robinson GW, Rudneva VA, Buchhalter I, Billups CA, Waszak SM, Smith KS, Bowers DC, Bendel A, Fisher PG, Partap S, Crawford JR, Hassall T, Indelicato DJ, Boop F, Klimo P, Sabin ND, Patay Z, Merchant TE, Stewart CF, Orr BA, Korbel JO, Jones DTW, Sharma T, Lichter P, Kool M, Korshunov A, Pfister SM, Gilbertson RJ, Sanders RP, Onar-Thomas A, Ellison DW, Gajjar A, Northcott PA.

Lancet Oncol. 2018 Jun;19(6):768-784. doi: 10.1016/S1470-2045(18)30204-3. Epub 2018 May 16.

PMID:
29778738
3.

Development and validation of a sensitive LC MS/MS method for the measurement of the checkpoint kinase 1 inhibitor prexasertib and its application in a cerebral microdialysis study.

Zhong B, Maharaj A, Davis A, Roussel MF, Stewart CF.

J Pharm Biomed Anal. 2018 Jul 15;156:97-103. doi: 10.1016/j.jpba.2018.04.018. Epub 2018 Apr 17.

PMID:
29698863
4.

Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma.

Broniscer A, Jia S, Mandrell B, Hamideh D, Huang J, Onar-Thomas A, Gajjar A, Raimondi SC, Tatevossian RG, Stewart CF.

Pediatr Blood Cancer. 2018 Jul;65(7):e27035. doi: 10.1002/pbc.27035. Epub 2018 Mar 7.

PMID:
29512900
5.

The durability of operational improvements with rotational patient assignment.

Traub SJ, Saghafian S, Bartley AC, Buras MR, Stewart CF, Kruse BT.

Am J Emerg Med. 2018 Aug;36(8):1367-1371. doi: 10.1016/j.ajem.2017.12.045. Epub 2017 Dec 20.

PMID:
29331271
6.

Establishing a Preclinical Multidisciplinary Board for Brain Tumors.

Nimmervoll BV, Boulos N, Bianski B, Dapper J, DeCuypere M, Shelat A, Terranova S, Terhune HE, Gajjar A, Patel YT, Freeman BB, Onar-Thomas A, Stewart CF, Roussel MF, Guy RK, Merchant TE, Calabrese C, Wright KD, Gilbertson RJ.

Clin Cancer Res. 2018 Apr 1;24(7):1654-1666. doi: 10.1158/1078-0432.CCR-17-2168. Epub 2018 Jan 4.

7.

Adductor focal laryngeal Dystonia: correlation between clinicians' ratings and subjects' perception of Dysphonia.

Stewart CF, Sinclair CF, Kling IF, Diamond BE, Blitzer A.

J Clin Mov Disord. 2017 Dec 13;4:20. doi: 10.1186/s40734-017-0066-y. eCollection 2017.

8.

A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specification.

Moj D, Britz H, Burhenne J, Stewart CF, Egerer G, Haefeli WE, Lehr T.

Cancer Chemother Pharmacol. 2017 Nov;80(5):1013-1026. doi: 10.1007/s00280-017-3447-x. Epub 2017 Oct 7.

9.

Bridging Adult Experience to Pediatrics in Oncology Drug Development.

Leong R, Zhao H, Reaman G, Liu Q, Wang Y, Stewart CF, Burckart G.

J Clin Pharmacol. 2017 Oct;57 Suppl 10:S129-S135. doi: 10.1002/jcph.910.

PMID:
28921643
10.

Development of Molecularly Targeted Therapies to Treat Pediatric Malignancies.

Stewart CF, Robinson GW.

Clin Pharmacol Ther. 2017 Nov;102(5):752-753. doi: 10.1002/cpt.785. Epub 2017 Aug 24. Review.

11.

A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy.

Navid F, Santana VM, Neel M, McCarville MB, Shulkin BL, Wu J, Billups CA, Mao S, Daryani VM, Stewart CF, Kunkel M, Smith W, Ward D, Pappo AS, Bahrami A, Loeb DM, Reikes Willert J, Rao BN, Daw NC.

Int J Cancer. 2017 Oct 1;141(7):1469-1477. doi: 10.1002/ijc.30841. Epub 2017 Jul 3.

12.

Derivation of new equations to estimate glomerular filtration rate in pediatric oncology patients.

Millisor VE, Roberts JK, Sun Y, Tang L, Daryani VM, Gregornik D, Cross SJ, Ward D, Pauley JL, Molinelli A, Brennan RC, Stewart CF.

Pediatr Nephrol. 2017 Sep;32(9):1575-1584. doi: 10.1007/s00467-017-3693-5. Epub 2017 Jun 2.

13.

Development and validation of LC-MS/MS methods for the measurement of ribociclib, a CDK4/6 inhibitor, in mouse plasma and Ringer's solution and its application to a cerebral microdialysis study.

Kala A, Patel YT, Davis A, Stewart CF.

J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Jul 1;1057:110-117. doi: 10.1016/j.jchromb.2017.05.002. Epub 2017 May 5.

14.

Palmar-plantar erythrodysesthesia syndrome following treatment with high-dose methotrexate or high-dose cytarabine.

Karol SE, Yang W, Smith C, Cheng C, Stewart CF, Baker SD, Sandlund JT, Rubnitz JE, Bishop MW, Pappo AS, Jeha S, Pui CH, Relling MV.

Cancer. 2017 Sep 15;123(18):3602-3608. doi: 10.1002/cncr.30762. Epub 2017 May 11.

15.

A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study.

Banerjee A, Jakacki RI, Onar-Thomas A, Wu S, Nicolaides T, Young Poussaint T, Fangusaro J, Phillips J, Perry A, Turner D, Prados M, Packer RJ, Qaddoumi I, Gururangan S, Pollack IF, Goldman S, Doyle LA, Stewart CF, Boyett JM, Kun LE, Fouladi M.

Neuro Oncol. 2017 Aug 1;19(8):1135-1144. doi: 10.1093/neuonc/now282.

16.

Population Pharmacokinetics of Selumetinib and Its Metabolite N-desmethyl-selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low-Grade Gliomas.

Patel YT, Daryani VM, Patel P, Zhou D, Fangusaro J, Carlile DJ, Martin PD, Aarons L, Stewart CF.

CPT Pharmacometrics Syst Pharmacol. 2017 May;6(5):305-314. doi: 10.1002/psp4.12175. Epub 2017 Mar 22. Erratum in: CPT Pharmacometrics Syst Pharmacol. 2017 Oct;6(10 ):719.

17.

Ocular Salvage and Vision Preservation Using a Topotecan-Based Regimen for Advanced Intraocular Retinoblastoma.

Brennan RC, Qaddoumi I, Mao S, Wu J, Billups CA, Stewart CF, Hoehn ME, Rodriguez-Galindo C, Wilson MW.

J Clin Oncol. 2017 Jan;35(1):72-77. Epub 2016 Oct 31.

18.

A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study.

Salloum R, Hummel TR, Kumar SS, Dorris K, Li S, Lin T, Daryani VM, Stewart CF, Miles L, Poussaint TY, Stevenson C, Goldman S, Dhall G, Packer R, Fisher P, Pollack IF, Fouladi M, Boyett J, Drissi R.

J Neurooncol. 2016 Sep;129(3):443-451. doi: 10.1007/s11060-016-2189-7. Epub 2016 Jun 27.

19.

Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021.

Wetmore C, Daryani VM, Billups CA, Boyett JM, Leary S, Tanos R, Goldsmith KC, Stewart CF, Blaney SM, Gajjar A.

Cancer Med. 2016 Jul;5(7):1416-24. doi: 10.1002/cam4.713. Epub 2016 Apr 25.

20.

Translational Pharmacokinetic-Pharmacodynamic Modeling and Simulation: Optimizing 5-Fluorouracil Dosing in Children With Pediatric Ependymoma.

Daryani VM, Patel YT, Tagen M, Turner DC, Carcaboso AM, Atkinson JM, Gajjar A, Gilbertson RJ, Wright KD, Stewart CF.

CPT Pharmacometrics Syst Pharmacol. 2016 Apr;5(4):211-221. doi: 10.1002/psp4.12075. Epub 2016 Apr 14.

21.

Population Pharmacokinetics of Oral Topotecan in Infants and Very Young Children with Brain Tumors Demonstrates a Role of ABCG2 rs4148157 on the Absorption Rate Constant.

Roberts JK, Birg AV, Lin T, Daryani VM, Panetta JC, Broniscer A, Robinson GW, Gajjar AJ, Stewart CF.

Drug Metab Dispos. 2016 Jul;44(7):1116-22. doi: 10.1124/dmd.115.068676. Epub 2016 Apr 6.

22.

Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype.

Phoenix TN, Patmore DM, Boop S, Boulos N, Jacus MO, Patel YT, Roussel MF, Finkelstein D, Goumnerova L, Perreault S, Wadhwa E, Cho YJ, Stewart CF, Gilbertson RJ.

Cancer Cell. 2016 Apr 11;29(4):508-522. doi: 10.1016/j.ccell.2016.03.002. Epub 2016 Mar 31.

23.

Feasibility of Pegylated Interferon in Children and Young Adults With Resected High-Risk Melanoma.

Navid F, Herzog CE, Sandoval J, Daryani VM, Stewart CF, Gattuso J, Mandrell B, Phipps S, Chemaitilly W, Sykes A, Davidoff AM, Shulkin BL, Bahrami A, Furman WL, Mao S, Wu J, Schiff D, Rao B, Pappo A.

Pediatr Blood Cancer. 2016 Jul;63(7):1207-13. doi: 10.1002/pbc.25983. Epub 2016 Apr 1.

24.

Simvastatin Hydroxy Acid Fails to Attain Sufficient Central Nervous System Tumor Exposure to Achieve a Cytotoxic Effect: Results of a Preclinical Cerebral Microdialysis Study.

Patel YT, Jacus MO, Davis AD, Boulos N, Turner DC, Vuppala PK, Freeman BB 3rd, Gilbertson RJ, Stewart CF.

Drug Metab Dispos. 2016 Apr;44(4):591-4. doi: 10.1124/dmd.115.068445. Epub 2016 Jan 22.

25.

Determination of Methotrexate, 7-Hydroxymethotrexate, and 2,4-Diamino-N10-methylpteroic Acid by LC-MS/MS in Plasma and Cerebrospinal Fluid and Application in a Pharmacokinetic Analysis of High-Dose Methotrexate.

Roberts MS, Selvo NS, Roberts JK, Daryani VM, Owens TS, Harstead KE, Gajjar A, Stewart CF.

J Liq Chromatogr Relat Technol. 2016;39(16):745-751. doi: 10.1080/10826076.2016.1243558. Epub 2016 Oct 10.

26.

Neurocognitive and Patient-Reported Outcomes in Adult Survivors of Childhood Osteosarcoma.

Edelmann MN, Daryani VM, Bishop MW, Liu W, Brinkman TM, Stewart CF, Mulrooney DA, Kimberg C, Ness KK, Cheung YT, Srivastava DK, Robison LL, Hudson MM, Krull KR.

JAMA Oncol. 2016 Feb;2(2):201-8. doi: 10.1001/jamaoncol.2015.4398.

27.

Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma.

Wright KD, Daryani VM, Turner DC, Onar-Thomas A, Boulos N, Orr BA, Gilbertson RJ, Stewart CF, Gajjar A.

Neuro Oncol. 2015 Dec;17(12):1620-7. doi: 10.1093/neuonc/nov181. Epub 2015 Nov 4.

28.

Preclinical studies of 5-fluoro-2'-deoxycytidine and tetrahydrouridine in pediatric brain tumors.

Morfouace M, Nimmervoll B, Boulos N, Patel YT, Shelat A, Freeman BB 3rd, Robinson GW, Wright K, Gajjar A, Stewart CF, Gilbertson RJ, Roussel MF.

J Neurooncol. 2016 Jan;126(2):225-34. doi: 10.1007/s11060-015-1965-0. Epub 2015 Oct 30.

29.

Assessing vascular effects of adding bevacizumab to neoadjuvant chemotherapy in osteosarcoma using DCE-MRI.

Guo J, Glass JO, McCarville MB, Shulkin BL, Daryani VM, Stewart CF, Wu J, Mao S, Dwek JR, Fayad LM, Madewell JE, Navid F, Daw NC, Reddick WE.

Br J Cancer. 2015 Nov 3;113(9):1282-8. doi: 10.1038/bjc.2015.351. Epub 2015 Oct 13.

30.

Emergency Department Rotational Patient Assignment.

Traub SJ, Stewart CF, Didehban R, Bartley AC, Saghafian S, Smith VD, Silvers SM, LeCheminant R, Lipinski CA.

Ann Emerg Med. 2016 Feb;67(2):206-15. doi: 10.1016/j.annemergmed.2015.07.008. Epub 2015 Oct 6.

PMID:
26452721
31.

Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature.

Jacus MO, Daryani VM, Harstead KE, Patel YT, Throm SL, Stewart CF.

Clin Pharmacokinet. 2016 Mar;55(3):297-311. doi: 10.1007/s40262-015-0319-6. Review.

32.

Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients.

Blitzer A, Brin MF, Stewart CF.

Laryngoscope. 2015 Aug;125(8):1751-7. doi: 10.1002/lary.25273. No abstract available.

PMID:
26200329
33.

ABCG2 Transporter Expression Impacts Group 3 Medulloblastoma Response to Chemotherapy.

Morfouace M, Cheepala S, Jackson S, Fukuda Y, Patel YT, Fatima S, Kawauchi D, Shelat AA, Stewart CF, Sorrentino BP, Schuetz JD, Roussel MF.

Cancer Res. 2015 Sep 15;75(18):3879-89. doi: 10.1158/0008-5472.CAN-15-0030. Epub 2015 Jul 21.

34.

A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors.

Kieran MW, Chi S, Goldman S, Onar-Thomas A, Poussaint TY, Vajapeyam S, Fahey F, Wu S, Turner DC, Stewart CF, Moses M, Packer RJ, Jakacki R, Banerjee A, Boyett JM, Fouladi M, Kun L.

Childs Nerv Syst. 2015 Sep;31(9):1433-45. doi: 10.1007/s00381-015-2812-5. Epub 2015 Jul 19.

35.

Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032.

Robinson GW, Orr BA, Wu G, Gururangan S, Lin T, Qaddoumi I, Packer RJ, Goldman S, Prados MD, Desjardins A, Chintagumpala M, Takebe N, Kaste SC, Rusch M, Allen SJ, Onar-Thomas A, Stewart CF, Fouladi M, Boyett JM, Gilbertson RJ, Curran T, Ellison DW, Gajjar A.

J Clin Oncol. 2015 Aug 20;33(24):2646-54. doi: 10.1200/JCO.2014.60.1591. Epub 2015 Jul 13.

36.

Observational Evaluations of Mice during Cerebral Microdialysis for Pediatric Brain Tumor Research.

Jacus MO, Rahija RJ, Davis AD, Throm SL, Stewart CF.

J Am Assoc Lab Anim Sci. 2015 May;54(3):304-10.

37.

Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study.

Hoffman LM, Fouladi M, Olson J, Daryani VM, Stewart CF, Wetmore C, Kocak M, Onar-Thomas A, Wagner L, Gururangan S, Packer RJ, Blaney SM, Gajjar A, Kun LE, Boyett JM, Gilbertson RJ.

Childs Nerv Syst. 2015 Aug;31(8):1283-9. doi: 10.1007/s00381-015-2725-3. Epub 2015 May 1.

38.

An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN).

DeWire M, Fouladi M, Turner DC, Wetmore C, Hawkins C, Jacobs C, Yuan Y, Liu D, Goldman S, Fisher P, Rytting M, Bouffet E, Khakoo Y, Hwang EI, Foreman N, Stewart CF, Gilbert MR, Gilbertson R, Gajjar A.

J Neurooncol. 2015 May;123(1):85-91. doi: 10.1007/s11060-015-1764-7. Epub 2015 Apr 10.

39.

Corrigendum: Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss.

Xu H, Robinson GW, Huang J, Lim JY, Zhang H, Bass JK, Broniscer A, Chintagumpala M, Bartels U, Gururangan S, Hassall T, Fisher M, Cohn R, Yamashita T, Teitz T, Zuo J, Onar-Thomas A, Gajjar A, Stewart CF, Yang JJ.

Nat Genet. 2015 Apr;47(4):423. doi: 10.1038/ng0415-423. No abstract available.

PMID:
25814313
40.

Preclinical examination of clofarabine in pediatric ependymoma: intratumoral concentrations insufficient to warrant further study.

Patel YT, Jacus MO, Boulos N, Dapper JD, Davis AD, Vuppala PK, Freeman BB 3rd, Mohankumar KM, Throm SL, Gilbertson RJ, Stewart CF.

Cancer Chemother Pharmacol. 2015 May;75(5):897-906. doi: 10.1007/s00280-015-2713-z. Epub 2015 Feb 28.

41.

Response to: comment on "Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections".

Wright KD, Stewart CF.

Cancer Chemother Pharmacol. 2015 Apr;75(4):877-8. doi: 10.1007/s00280-015-2699-6. Epub 2015 Feb 26. No abstract available.

42.

Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss.

Xu H, Robinson GW, Huang J, Lim JY, Zhang H, Bass JK, Broniscer A, Chintagumpala M, Bartels U, Gururangan S, Hassall T, Fisher M, Cohn R, Yamashita T, Teitz T, Zuo J, Onar-Thomas A, Gajjar A, Stewart CF, Yang JJ.

Nat Genet. 2015 Mar;47(3):263-6. doi: 10.1038/ng.3217. Epub 2015 Feb 9. Erratum in: Nat Genet. 2015 Apr;47(4):423.

43.

Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients.

Scott JR, Zhou Y, Cheng C, Ward DA, Swanson HD, Molinelli AR, Stewart CF, Navid F, Jeha S, Relling MV, Crews KR.

Pediatr Blood Cancer. 2015 Sep;62(9):1518-22. doi: 10.1002/pbc.25395. Epub 2015 Jan 28.

44.

Population pharmacokinetic analysis of oxaliplatin in adults and children identifies important covariates for dosing.

Nikanjam M, Stewart CF, Takimoto CH, Synold TW, Beaty O, Fouladi M, Capparelli EV.

Cancer Chemother Pharmacol. 2015 Mar;75(3):495-503. doi: 10.1007/s00280-014-2667-6. Epub 2015 Jan 4.

45.

Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study.

Packer RJ, Rood BR, Turner DC, Stewart CF, Fisher M, Smith C, Young-Pouissant T, Goldman S, Lulla R, Banerjee A, Pollack I, Kun L, Onar-Thomas A, Wu S, Boyett JM, Fouladi M.

J Neurooncol. 2015 Jan;121(1):217-24. doi: 10.1007/s11060-014-1665-1. Epub 2014 Nov 19.

46.

Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells.

Vilgelm AE, Pawlikowski JS, Liu Y, Hawkins OE, Davis TA, Smith J, Weller KP, Horton LW, McClain CM, Ayers GD, Turner DC, Essaka DC, Stewart CF, Sosman JA, Kelley MC, Ecsedy JA, Johnston JN, Richmond A.

Cancer Res. 2015 Jan 1;75(1):181-93. doi: 10.1158/0008-5472.CAN-14-2405. Epub 2014 Nov 14.

47.

Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections.

Wright KD, Panetta JC, Onar-Thomas A, Reddick WE, Patay Z, Qaddoumi I, Broniscer A, Robinson G, Boop FA, Klimo P Jr, Ward D, Gajjar A, Stewart CF.

Cancer Chemother Pharmacol. 2015 Jan;75(1):27-35. doi: 10.1007/s00280-014-2614-6. Epub 2014 Oct 24.

48.

Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors.

Brennan RC, Furman W, Mao S, Wu J, Turner DC, Stewart CF, Santana V, McGregor LM.

Cancer Chemother Pharmacol. 2014 Dec;74(6):1191-8. doi: 10.1007/s00280-014-2593-7. Epub 2014 Sep 26.

49.

Determination of crizotinib in human and mouse plasma by liquid chromatography electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS).

Roberts MS, Turner DC, Broniscer A, Stewart CF.

J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Jun 1;960:151-7. doi: 10.1016/j.jchromb.2014.04.035. Epub 2014 Apr 28.

50.

Pemetrexed and gemcitabine as combination therapy for the treatment of Group3 medulloblastoma.

Morfouace M, Shelat A, Jacus M, Freeman BB 3rd, Turner D, Robinson S, Zindy F, Wang YD, Finkelstein D, Ayrault O, Bihannic L, Puget S, Li XN, Olson JM, Robinson GW, Guy RK, Stewart CF, Gajjar A, Roussel MF.

Cancer Cell. 2014 Apr 14;25(4):516-29. doi: 10.1016/j.ccr.2014.02.009. Epub 2014 Mar 27.

Supplemental Content

Loading ...
Support Center